Maya Goldman
Maya Goldman is a health policy reporter with a focus on Congress and federal agencies, particularly Medicare payment, telehealth, and price transparency. She has a background in this field from her previous work at Modern Healthcare. Maya's articles often cover topics related to these primary areas of interest. While no specific conflicts of interest are identified in her current reporting, her narrow focus may sometimes lead to a slant in her reporting.
Biography:
https://www.axios.com/authors/mgoldman
71%
The Daily's Verdict
This author has a mixed reputation for journalistic standards. It is advisable to fact-check, scrutinize for bias, and check for conflicts of interest before relying on the author's reporting.
Bias
90%
Examples:
- Maya Goldman has a background in health policy and focuses on Congress and federal agencies, particularly Medicare payment, telehealth, and price transparency. This narrow focus may lead to a slant in her reporting.
Conflicts of Interest
75%
Examples:
- Maya Goldman previously worked for Modern Healthcare, a publication that may have conflicts of interest with other organizations in the health industry. However, no specific conflicts of interest are identified in her current reporting.
Contradictions
86%
Examples:
- In an article about bird flu, Maya Goldman mentions that the human case cannot yet be definitively linked to recent poultry outbreaks while also stating that at least three people in the US have been diagnosed with bird flu since March and were all workers at farms with infected cows. This creates confusion around the source of the bird flu cases.
- In an article about Medicare coverage for weight-loss drugs, Maya Goldman claims that Medicare can start covering a popular weight-loss drug for more people when it has been barred from paying for weight-loss drugs. This is deceptive because Medicare cannot cover the drug, only other approved indications such as diabetes.
Deceptions
45%
Examples:
- In an article about Medicare coverage for weight-loss drugs, Maya Goldman makes a deceptive statement by claiming that Medicare can start covering a popular weight-loss drug for more people when it has been barred from paying for weight-loss drugs. This is deceptive because Medicare cannot cover the drug, only other approved indications such as diabetes.
Recent Articles
First Human Death from Highly Pathogenic Avian Influenza A(H5N2) Virus Reported in Mexico
Broke On: Monday, 24 April 2023A 59-year-old Mexican resident became the first human fatality of avian influenza A(H5N2) in April 2023, despite no known contact with infected animals. The WHO confirmed the high pathogenicity of this strain, which had previously been detected in a Michoacán poultry farm. Contact tracing revealed only one potential exposure, and the risk to the general population remains low. Wegovy Approved to Reduce Heart Complications in Overweight People with Cardiovascular Disease by 20%
Broke On: Monday, 18 March 2024Wegovy, a weight loss drug approved by the FDA for reducing cardiovascular risks in overweight people with heart disease, is now being used to reduce the risk of major heart complications including heart attack, stroke or cardiovascular-related deaths. The new label expansion for Wegovy indicates that it can be used to reduce these risks by 20% in this population. This approval opens up a new market for weight loss drugs and could greatly expand older adults' access to treatments that so far have been limited.
